[The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
The use of beta-interferons for immunomodulating treatment of multiple sclerosis (MS) in children is rstudied. We present results of the prospective study of 22 children, aged 13-17 years, with MS treated with beta-interferon-1b (betaferon) during 2-15 (mean 10,72) months. High efficacy and good tolerability of beta-interferon-1b is demonstrated.
Bykova
O V
OV
Kuzenkova
L M
LM
Maslova
O I
OI
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D002648:Child; D003866:Depressive Disorder / Q000453:epidemiology / Q000523:psychology; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta